COMMUNIQUÉS West-GlobeNewswire

NEXGEL and STADA Partner to Launch Leading European DAO Enzyme Supplement, Histasolv, in North America
11/06/2024
LANGHORNE, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content [...]
Sofwave Medical Receives Marketing Clearance in Canada for Pure Impact™ Strength and Muscle Toning Device
11/06/2024
– Approval by Health Canada regulatory authority immediately clears the way for Pure Impact™ with PlyoPulse™ device launch and commercialization in Canada – Canada Represents Another Substantial Market Opportunity for [...]
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 18, 2024
11/06/2024
CAMBRIDGE, Mass., June 11, 2024 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, President [...]
SeaStar Medical’s Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology
11/06/2024
DENVER, June 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on [...]
Palisade Bio Announces Notice of Allowance for Canadian Patent Covering Lead Product Candidate, PALI-2108
11/06/2024
PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Company on track to commence Phase 1 human clinical study of PALI-2108 for the treatment of UC before year end [...]
Faraday Pharmaceuticals Announces Completion of Enrollment in Pivotal Phase 3 Iocyte AMI-3 Trial of FDY-5301
11/06/2024
2,300 patients in trial enrolled ahead of schedule 12-month follow up period underway, with topline data anticipated in 2H 2025 Trial designed with 90% power to detect a 30% reduction in the primary outcome of heart [...]
Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer
11/06/2024
Eight of 12 evaluable patients (66.7%) had progression-free survival (PFS) ranging from 5 to 11 months At the highest NGC-Cap dose, all three evaluable patients had PFS with two partial responses (PR) and one stable [...]
Skyhawk Therapeutics Promotes Clint Musil to Chief Executive Officer and Appoints Co-founder Bill Haney to Executive Chairman
11/06/2024
BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced the [...]
ONCOTELIC TO PRESENT AT THE 20TH ANNUAL CONGRESS OF INTERNATIONAL DRUG DISCOVERY SCIENCE & TECHNOLOGY
11/06/2024
AGOURA HILLS, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its CEO- Dr. Vuong Trieu will speak at the 20th Annual Congress of International Drug Discovery Science [...]
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
11/06/2024
- Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- CervoMed [...]
Allyx Therapeutics Announces First Alzheimer’s Disease Patient Treated with Lead Compound ALX-001
11/06/2024
With Growing Body of Clinical Evidence, ALX-001 is Ready to Commence Phase 2 Studies NEW HAVEN, Conn., June 11, 2024 (GLOBE NEWSWIRE) -- Allyx Therapeutics, a clinical-stage biotechnology company working to deliver a [...]
RenovoRx Appoints Ryan Witt as Senior Vice President, Head of Corporate Strategy and Partnerships
10/06/2024
New role highlights RenovoRx’s commitment to explore and execute on clinical and commercial business development opportunities with its therapeutic technology LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- [...]
GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
10/06/2024
-- New integration to streamline access for health systems and improve provider and patient journeys using Epic for electronic connections -- -- Increases commercial footprint and focus on accelerating utilization of [...]
SeaStar Medical Strengthens Board of Directors and Transitions to Commercial-Stage Company
10/06/2024
DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) announces that three new members have joined its Board of Directors. Two new directors, Jennifer A. Baird and [...]
Novo Nordisk A/S - share repurchase programme
10/06/2024
Bagsværd, Denmark, 10 June 2024 – On 6 May 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
10/06/2024
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) [...]
LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024
10/06/2024
Capstone data from Phase 3 CLARITY study to be presented Event to feature Key Opinion Leader and Principal Investigator perspectives on LNZ100 potential in presbyopia SAN DIEGO, June 10, 2024 (GLOBE NEWSWIRE) -- LENZ [...]
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366
10/06/2024
– Phase 1a study portion of single ascending dosing in healthy participants will inform the development of ABI-5366 with interim data expected in Q3 2024 – – Phase 1b study portion of multiple ascending weekly doses in [...]
InnovAge Holding Corp. Announces $5.0 Million Share Repurchase Program
10/06/2024
DENVER, June 10, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (NASDAQ: INNV) (the “Company” or “InnovAge”) announced today that its Board of Directors has approved a share repurchase program (the “Program”) that [...]

Pages